Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.53 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elisartan SCHEMBL489079 | 1.00 | AGTR1 (0.53) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL29595840 | 0.99 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL1560942 | 0.99 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL615371 | 0.99 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL615370 | 0.99 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| SCHEMBL12990879 | 0.93 | AGTR2 (0.53) | AGTR1AGTR2PPARG | |
| SCHEMBL6130076 | 0.92 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL4609266 | 0.92 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL12991717 | 0.91 | AGTR2 (0.51) | AGTR1AGTR2 | |
| SCHEMBL13771416 | 0.91 | AGTR1 (0.48) | AGTR1AGTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 824 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| EP-3873904-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2024-07-10 | — | — | EP | claimed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | claimed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | claimed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | claimed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | claimed |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-10-27 | — | — | US | claimed |
| US-20060167045-A1 | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist | MERCK & CO., INC. | 2006-07-27 | — | — | US | claimed |
| EP-1667643-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| US-6984633-B2 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and epoxymexrenone | G.D SEARLE & CO. (US) | 2006-01-10 | — | — | US | claimed |
| WO-2006000564-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEP-INHIBITORS, INHIBITORS OF THE ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND AT1-RECEPTOR ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-01-05 | — | — | WO | claimed |
| US-20050288272-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-12-29 | — | — | US | claimed |
| EP-1545540-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| WO-2004017896-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | claimed |
| US-6653306-B1 | Circulatory disorders | G.D. SEARLE & CO. | 2003-11-25 | — | — | US | claimed |
| EP-0831911-B1 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | SEARLE & CO (US) | 2002-04-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 5/4885AGTR2 11/4885PPARG 4731/4885 |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | AGTR1 25/4885AGTR2 42/4885PPARG 3055/4885 |
| US-20060167045-A1 | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist | AGTR2, AGTR1, PPARA | AGTR1 2/4885AGTR2 1/4885PPARG 4/4885 |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885AGTR2 868/4885PPARG 876/4885 |
| US-20050288272-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists | ECE1, EDNRA, MME | AGTR1 6/4885AGTR2 7/4885PPARG 2750/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 4/4885AGTR2 13/4885PPARG 4587/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 4/4885AGTR2 9/4885PPARG 4814/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 5/4885AGTR2 11/4885PPARG 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.